



## Oncocyte to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday March 10

Mar 01, 2022

IRVINE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that it will release its financial and operating results for the fourth quarter and year ended December 31, 2021, on Thursday, March 10, 2022, after the close of the U.S. financial markets. The Company will host a conference call on Thursday, March 10, 2022, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.

The dial-in number in the U.S./Canada is 877-407-9716; for international participants, the number is 201-493-6779. For all callers, please refer to Conference ID 13726740. To access the live webcast, go to the investor relations section on the Company's website, or by clicking here:

[https://viaid.webcasts.com/starthere.jsp?ei=1526783&tp\\_key=769c96014b](https://viaid.webcasts.com/starthere.jsp?ei=1526783&tp_key=769c96014b)

### **About Oncocyte**

Oncocyte is a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives by accelerating the diagnosis of cancer and advancing cancer care. The Company's tests are designed to help provide clarity and confidence to physicians and their patients at every stage. DetermaRx™ identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy. DetermaIO™, a gene expression test currently used as a research-use only tool, assesses the tumor microenvironment to predict response to immunotherapies. The Company's pipeline of tests in development also includes DetermaTx™, which will assess mutational status of a tumor, blood-based monitoring test DetermaCNI™, and long-term recurrence monitoring test DetermaMx™. In addition, Oncocyte's pharmaceutical services provide companies that are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

DetermaRx™, DetermaIO™, DetermaTx™, DetermaCNI™, DetermaMx™ and TheraSure™ are trademarks of Oncocyte Corporation.

Investor Contact  
Bob Yedid  
LifeSci Advisors, LLC

646-597-6989

[bob@lifesciadvisors.com](mailto:bob@lifesciadvisors.com)

Media Contact

Megan Kernan

ICR Westwicke Healthcare PR

646-677-1870

[Megan.Kernan@westwicke.com](mailto:Megan.Kernan@westwicke.com)

Source: Oncocyte Corporation



Source: Oncocyte Corporation

